Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 624

Sort by

Sort Order Select

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Masayuki Shiseki, MD PhD, Mayuko Ishii, Mari Ohwashi, Kentaro Yoshinaga, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 4258.

https://doi.org/10.1182/blood-2019-124738

Published: 2019

Journal Articles

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Blood (2019) 134 (Supplement_1): 1709.

https://doi.org/10.1182/blood-2019-122032

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

David P. Steensma, MD, Rami S. Komrokji, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Andrew M. Brunner, MD, Richard M. Stone, MD, John Barnard, PhD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2018-99-117538

Published: 2018

Journal Articles

Treatment with Decitabine Followed By Prednisone for Myelodysplatic Syndrome Concomitant with Sjogren's Syndrome

Xingfu Sun, Jianyong Li, MD, Hua Lu, MD PhD

Blood (2018) 132 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2018-99-112020

Published: 2018

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Amer M. Zeidan, MBBS, MHS, Weiwei Zhu, MPH, Rong Wang, PhD, Maximilian Stahl, MD, Scott F Huntington, MDMPH, Smith Giri, MBBS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, MD PhD, Amy J. Davidoff, PhD MS

Blood (2018) 132 (Supplement 1): 838.

https://doi.org/10.1182/blood-2018-99-116497

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

Molecular Features in the Diagnosis of Myeloid Neoplasms in Down Syndrome Patients Less Than Four Years of Age: Experience from a Single Institution

Chris Ours, MD, Fiorella Iglesias, MD, Erin Morales, MD, Luke Maese, DO, Archana M Agarwal, MD, Anupam Verma, MD

Blood (2018) 132 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2018-99-120304

Published: 2018

Journal Articles

DNMT3A Is Highly Expressed in Bone Marrow Cells from Acute Myeloid Leukemia Patients

Renata Scopim Ribeiro, BSc, MSc, João Agostinho Machado-Neto, BSc, Paula De Melo Campos, MD PhD, Christopher A. Eide, Samantha L Savage, Irene Lorand-Metze, MD PhD, Cristina E. Tognon, PhD, Fernando Ferreira Costa, MD PhD, Brian J. Druker, MD, Sara Teresinha Olalla Saad, MD PhD, Fabiola Traina, MD PhD

Blood (2017) 130 (Supplement 1): 3969.

https://doi.org/10.1182/blood.V130.Suppl_1.3969.3969

Published: 2017

Journal Articles

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Irene Glezou, MD, Sotirios Papageorgiou, MD PhD, Efthimia Bazani, MD, Diamantina Vasilatou, MD, Nora Viniou, MD, Athanasios Galanopoulos, MD PhD, Kalliopi Zafeiropoulou, Kotsianidis Ioannis, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 3825.

https://doi.org/10.1182/blood.V130.Suppl_1.3825.3825

Published: 2017

Journal Articles

Programmed Necrosis Correlates with Development and Progression of Myelodysplastic Syndromes

Jing Zou, PhD MD, Qiong Shi, M.S., Patrice N. Wagner, PhD, Michael R. Savona, MD, Ridas Juskevicious, MD, Heidi Chen, PhD, Sandra S. Zinkel, MD PhD

Blood (2017) 130 (Supplement 1): 4229.

https://doi.org/10.1182/blood.V130.Suppl_1.4229.4229

Published: 2017

Journal Articles

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, MD PhD, Jeroen Simon Goede, Agnes Guerci-Bresler, Michel Delforge, MDPhD, Esther Natalie Oliva, MD, Jiri Mayer, Prof, MD SCs, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao

Blood (2017) 130 (Supplement 1): 4271.

https://doi.org/10.1182/blood.V130.Suppl_1.4271.4271

Published: 2017

Journal Articles

Description of Mutational Profile in Patients with Lower-Risk Myelodysplastic Syndromes at the Time of Leukemic Progression

Begoña Pedrote, Jose Francisco Falantes, Estrella Carrillo, Cristina Calderon-Cabrera, Francisco J Marquez-Malaver, Ildefonso Espigado, MD PhD, Jose A. Perez-Simon, MD PhD

Blood (2017) 130 (Supplement 1): 5301.

https://doi.org/10.1182/blood.V130.Suppl_1.5301.5301

Published: 2017

NARROW

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Treatment with Decitabine Followed By Prednisone for Myelodysplatic Syndrome Concomitant with Sjogren's Syndrome

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Molecular Features in the Diagnosis of Myeloid Neoplasms in Down Syndrome Patients Less Than Four Years of Age: Experience from a Single Institution

DNMT3A Is Highly Expressed in Bone Marrow Cells from Acute Myeloid Leukemia Patients

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Programmed Necrosis Correlates with Development and Progression of Myelodysplastic Syndromes

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Description of Mutational Profile in Patients with Lower-Risk Myelodysplastic Syndromes at the Time of Leukemic Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only